Each year BIO brings the patient stakeholder community together for theto network; to learn; to engage; to partner; and to discover.
Held this year—its seventh—at the Park Hyatt hotel in Washington, DC, the Summit concluded today after running a robust program focused squarely on patients and their immeasurable contributions to the drug development process.
The two days of educational panels addressed best practices for engaging with industry, patient access to life-saving medicines, the opioid crisis, the FDA’s “Patient-Focused Drug Development” guidance and the Trump Administration’s “American Patients First Blueprint”—a proposed plan for addressing the cost of prescription drugs. Two of the sessions were live streamed on Facebook.
The intimate setting for the event was perfect for the lunchtime roundtable discussions hosted by subject matter experts from drug development companies and BIO staff. Attendees could choose from among 12 different subject areas which included such diverse topics as unconscious bias in clinical research, genome editing, Medicare Part B access and newborn screening—to name a few.
BIO’s One-on-one Partnering™ offered attendees individual meetings with potential collaborators, patient groups, industry reps and other stakeholders. This more targeted networking opportunity helped participants connect with the right people, enhancing their chances for building alliances that address unmet medical needs.
We talked with several attendees about their experience at the summit.